DRG Market Assessment reports

The rising rates of antimicrobial resistance (AMR) have created an emergent need for development and discovery of antibiotics with activity against drug-resistant gram-negative pathogens (GNPs)…

Clarivate Epidemiology’s coverage of polycythemia vera (PV) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France,…

The PsA therapy market has become highly dynamic with the recent launches of targeted agents such as AbbVie’s Rinvoq and Skyrizi and UCB’s bimekizumab. Upcoming launches in the next few years will…

Eli Lilly / Boehringer Ingelheim’s Abasaglar / Basaglar was the first biosimilar / follow-on insulin glargine to launch in Europe and the United States, followed by Sanofi’s Admelog / Insulin…

Antibody-drug conjugates have solidified their position as valuable tools against cancer. The agents combine the selectivity of monoclonal antibodies with the potency of cytotoxic drugs. The…

In 2019, Amgen / Allergan’s trastuzumab biosimilar Kanjinti and bevacizumab biosimilar Mvasi were the first monoclonal antibody (MAb) biosimilars launched in the United States, followed by…

Clarivate Epidemiology’s coverage of herpes zoster comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany,…

Vaccination programs have had a revolutionary impact on global public health, not only dramatically reducing the incidence of infectious disease but also reducing childhood and adult mortality and…

Clarivate Epidemiology’s coverage of neuroendocrine tumors (NETs) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and…

Clarivate Epidemiology’s coverage of neuroendocrine tumors (NETs) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and…

Clarivate Epidemiology’s coverage of neuroendocrine tumors (NETs) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and…

Clarivate Epidemiology’s coverage of neuroendocrine tumors (NETs) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and…